Updated efficacy and > 1-y follow up from IMvigor210: Atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (mUC).

被引：4

作者：

Dreicer, Robert

Hoffman-Censits, Jean H.

Flaig, Thomas W.

Grande, Enrique

Balmanoukian, Ani Sarkis

von Amsberg, Gunhild

Theodore, Christine

Chowdhury, Simon

Bracarda, Sergio

Clement, Jessica Mary

Yu, Evan Y.

Kalebasty, Arash Rezazadeh

Niegisch, Guenter

Culine, Stephane

Gordon, Michael S.

Cui, Na

Mariathasan, Sanjeev

Legrand, Fatema A.

Abidoye, Oyewale O.

Petrylak, Daniel Peter

机构：

[1] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA

[2] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA

[3] Univ Colorado, Canc Ctr, Aurora, CO USA

[4] Hosp Univ Ramon y Cajal, Dept Med Oncol, Madrid, Spain

[5] Angeles Clin & Res Inst, Los Angeles, CA USA

[6] 6Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[7] Hosp Foch, Suresnes, France

[8] Guys Hosp, London, England

[9] Kings Hosp, London, England

[10] St Thomas Hosp, London, England

[11] Osped San Donato USL8, Med Oncol, Ist Toscano Tumori, Arezzo, Italy

[12] Univ Connecticut, Ctr Hlth, Carole & Ray Neag Comprehens Canc Ctr, Farmington, CT USA

[13] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[14] Norton Canc Inst, Louisville, KY USA

[15] Heinrich Heine Univ, Dept Urol, Dusseldorf, Germany

[16] Hop St Louis, Paris, France

[17] HonorHlth Res Inst, Pinnacle Oncol Hematol, Scottsdale, AZ USA

[18] Genentech Inc, San Francisco, CA 94080 USA

[19] Roche Genentech, San Francisco, CA USA

[20] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA

[21] Yale Univ, New Haven, CT USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.4515

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4515

引用

页数：2

共 50 条

[21] CLINICAL CHARACTERISTICS ASSOCIATED WITH EARLY PROGRESSION OR LONG-TERM RESPONSE FROM THE PHASE II IMVIGOR210 STUDY: ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
Joseph, Richard W.
Loriot, Yohann
Luis Perez-Gracia, Jose
Dreicer, Robert
Petrylak, Daniel P.
van der Heijden, Michiel S.
Hoffman-Censits, Jean
Shen, Xiadong
Fear, Simon
Pavlova, Julie
Rosenberg, Jonathan E.
JOURNAL OF UROLOGY, 2018, 199 (04): : E1039 - E1039
[22] Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Hoffman-Censits, J.
Rosenberg, J. E.
van Der Heijden, M.
Dreicer, R.
Perez Gracia, J. L.
Petrylak, D. P.
Retz, M. M.
Sabbatini, R.
Naglieri, E.
Caserta, C.
Maruzzo, M.
Iacovelli, R.
Galli, L.
McDermott, R.
Morales Barrera, R.
Bonfill, T.
De Ducla, S.
Ding, B.
Linsenmeier, J.
Sternberg, C. N.
ANNALS OF ONCOLOGY, 2019, 30 : 372 - +
[23] Atezolizumab (atezo) vs chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): immune biomarkers, tumor mutational burden (TMB) and clinical outcomes from the Phase III IMvigor211 study
von Amsberg, G.
Powles, T.
Loriot, Y.
Ravaud, A.
Vogelzang, N. J.
Duran, I.
Retz, M.
De Giorgi, U.
Oudard, S.
Bamias, A.
Koeppen, H.
Leng, N.
Kadel, E. E.
Hegde, P. S.
Cui, N.
Shen, X.
Green, M.
Banchereau, R.
Mariathasan, S.
van der Heijden, M. S.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 325 - 326
[24] THE IMMUNE-RELATED ADVERSE EVENTS PARADOX IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER PATIENTS RECEIVING ATEZOLIZUMAB: ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM IMVIGOR210 AND IMVIGOR211
Robesti, Daniele
Nocera, Luigi
Belladelli, Federico
Schultz, Julianne G.
Fallara, Giuseppe
Marandino, Laura
Raggi, Daniele
Montorsi, Francesco
Necchi, Andrea
Martini, Alberto
JOURNAL OF UROLOGY, 2023, 209 : E244 - E245
[25] The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer patients receiving atezolizumab: Analysis of individual participant data from IMvigor210 and IMvigor211
Robesti, D.
Nocera, L.
Belladelli, F.
Schultz, J. G.
Fallara, G.
Marandino, L.
Raggi, D.
Montorsi, F.
Necchi, A.
Martini, A.
EUROPEAN UROLOGY, 2023, 83 : S763 - S764
[26] IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
Grande, E.
Galsky, M.
Arranz Arija, J. A.
De Santis, M.
Davis, I. D.
De Giorgi, U. F. F.
Mencinger, M.
Kikuchi, E.
Garcia del Muro, X.
Gumus, M.
Ozguroglu, M.
Kalebasty, A. Rezazadeh
Park, S. H.
Alekseev, B. Y.
Schutz, F. A. B.
Li, J-R.
Mecke, A.
Mariathasan, S.
Thastrom, A.
Bamias, A.
ANNALS OF ONCOLOGY, 2019, 30 : 888 - +
[27] The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: analysis of individual patient data from IMvigor210 and IMvigor211 trials
Robesti, Daniele
Nocera, Luigi
Belladelli, Federico
Schultz, Julianne G. G.
Fallara, Giuseppe
Marandino, Laura
Raggi, Daniele
Montorsi, Francesco
Msaouel, Pavlos
Necchi, Andrea
Martini, Alberto
BJU INTERNATIONAL, 2024, 133 (02) : 158 - 168
[28] Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.
Powles, Thomas
Loriot, Yohann
Ravaud, Alain
Vogelzang, Nicholas J.
Duran, Ignacio
Retz, Margitta
De Giorgi, Ugo
Oudard, Stephane
Bamias, Aristotelis
Koeppen, Hartmut
Leng, Ning
Kadel, Edward E.
Hegde, Priti S.
Cui, Na
Shen, Xiaodong
Derleth, Christina Louise
Green, Marjorie C.
Banchereau, Romain
Mariathasan, Sanjeev
Van Der Heijden, Michiel Simon
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[29] Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): A long-term overall survival (OS) and safety update from the phase III IMvigor211 study
Van der Heijden, M. S.
Loriot, Y.
Duran, I.
Ravaud, A.
Retz, M. M.
Vogelzang, N. J.
Nelson, B.
Wang, J.
Shen, X.
Powles, T.
ANNALS OF ONCOLOGY, 2019, 30
[30] Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
Sotelo, M.
Alonso-Gordoa, T.
Gajate, P.
Gallardo, E.
Morales-Barrera, R.
Perez-Gracia, J. L.
Puente, J.
Sanchez, P.
Castellano, D.
Duran, I.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (04): : 882 - 891

← 1 2 3 4 5 →